[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212-547-9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend", "age": 42, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 864335, "exercisedValue": 0, "unexercisedValue": 6398299}, {"maxAge": 1, "name": "Dr. Eric  Adler M.D.", "age": 49, "title": "Chief Medical Officer & Head of Research", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 623400, "exercisedValue": 0, "unexercisedValue": 586874}, {"maxAge": 1, "name": "Ms. Jenny R. Robertson J.D.", "age": 48, "title": "Chief Business & Legal Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 617900, "exercisedValue": 0, "unexercisedValue": 94692}, {"maxAge": 1, "name": "Dr. Ronald G. Crystal M.D.", "title": "Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rand  Monaghan", "title": "Vice President of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jose Manuel Otero Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 52, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  McHenry", "title": "VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.13, "open": 7.01, "dayLow": 6.78, "dayHigh": 7.2716, "regularMarketPreviousClose": 7.13, "regularMarketOpen": 7.01, "regularMarketDayLow": 6.78, "regularMarketDayHigh": 7.2716, "forwardPE": -2.2834384, "volume": 166080, "regularMarketVolume": 166080, "averageVolume": 435762, "averageVolume10days": 332590, "averageDailyVolume10Day": 332590, "bid": 5.04, "ask": 8.81, "bidSize": 200, "askSize": 200, "marketCap": 227573200, "fiftyTwoWeekLow": 5.77, "fiftyTwoWeekHigh": 22.33, "fiftyDayAverage": 8.1107, "twoHundredDayAverage": 12.056125, "currency": "USD", "enterpriseValue": 90110120, "floatShares": 16976826, "sharesOutstanding": 33077500, "sharesShort": 2193871, "sharesShortPriorMonth": 2073094, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0664, "heldPercentInsiders": 0.00487, "heldPercentInstitutions": 0.91483, "shortRatio": 6.55, "shortPercentOfFloat": 0.074200004, "impliedSharesOutstanding": 33077500, "bookValue": 4.261, "priceToBook": 1.6146444, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -77215000, "trailingEps": -12.64, "forwardEps": -2.77, "enterpriseToEbitda": -1.106, "52WeekChange": -0.49411762, "SandP52WeekChange": 0.2764505, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "LXEO", "underlyingSymbol": "LXEO", "shortName": "Lexeo Therapeutics, Inc.", "longName": "Lexeo Therapeutics, Inc.", "firstTradeDateEpochUtc": 1699018200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ab1fdece-ecd1-3551-bd81-6134d29606b5", "messageBoardId": "finmb_625814286", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.88, "targetHighPrice": 28.0, "targetLowPrice": 16.0, "targetMeanPrice": 22.28571, "targetMedianPrice": 23.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 174980992, "totalCashPerShare": 5.293, "ebitda": -81464000, "totalDebt": 10852000, "quickRatio": 9.27, "currentRatio": 9.384, "debtToEquity": 6.579, "returnOnAssets": -0.39933997, "returnOnEquity": -0.74834996, "freeCashflow": -36829752, "operatingCashflow": -62949000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]